Modjtahedi H - Search Results

1

Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy.

Eccles SA, Modjtahedi H, Box G, Court W, Sandle J, Dean CJ. Eccles SA, et al. Among authors: modjtahedi h. Invasion Metastasis. 1994-1995;14(1-6):337-48. Invasion Metastasis. 1994. PMID: 7657527 Review.

2

Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor.

Modjtahedi H, Eccles SA, Box G, Styles J, Dean CJ. Modjtahedi H, et al. Cell Biophys. 1993 Jan-Jun;22(1-3):129-46. doi: 10.1007/BF03033871. Cell Biophys. 1993. PMID: 7534211

3

Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.

Modjtahedi H, Eccles S, Box G, Styles J, Dean C. Modjtahedi H, et al. Br J Cancer. 1993 Feb;67(2):254-61. doi: 10.1038/bjc.1993.49. Br J Cancer. 1993. PMID: 7679281 Free PMC article.

4

The binding of HB-EGF to tumour cells is blocked by mAbs which act as EGF and TGF alpha antagonists.

Modjtahedi H, Dean C. Modjtahedi H, et al. Biochem Biophys Res Commun. 1995 Feb 6;207(1):389-97. doi: 10.1006/bbrc.1995.1200. Biochem Biophys Res Commun. 1995. PMID: 7857293

5

The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.

Modjtahedi H, Styles JM, Dean CJ. Modjtahedi H, et al. Br J Cancer. 1993 Feb;67(2):247-53. doi: 10.1038/bjc.1993.48. Br J Cancer. 1993. PMID: 8094290 Free PMC article.

6

Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.

Modjtahedi H, Eccles S, Sandle J, Box G, Titley J, Dean C. Modjtahedi H, et al. Cancer Res. 1994 Apr 1;54(7):1695-701. Cancer Res. 1994. PMID: 8137284

7

Immunotherapy with antibodies to the EGF receptor.

Dean C, Modjtahedi H, Eccles S, Box G, Styles J. Dean C, et al. Among authors: modjtahedi h. Int J Cancer Suppl. 1994;8:103-7. doi: 10.1002/ijc.2910570722. Int J Cancer Suppl. 1994. PMID: 8194887

8

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.

Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C, Gore M. Modjtahedi H, et al. Br J Cancer. 1996 Jan;73(2):228-35. doi: 10.1038/bjc.1996.40. Br J Cancer. 1996. PMID: 8546911 Free PMC article. Clinical Trial.

9

Monoclonal antibodies to the EGF receptor act as betacellulin antagonists.

Modjtahedi H, Dean C. Modjtahedi H, et al. Biochem Biophys Res Commun. 1996 Apr 25;221(3):625-30. doi: 10.1006/bbrc.1996.0646. Biochem Biophys Res Commun. 1996. PMID: 8630011

10

Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.

Modjtahedi H, Komurasaki T, Toyoda H, Dean C. Modjtahedi H, et al. Int J Cancer. 1998 Jan 19;75(2):310-6. doi: 10.1002/(sici)1097-0215(19980119)75:2<310::aid-ijc22>3.0.co;2-f. Int J Cancer. 1998. PMID: 9462724

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

79 results

Search Page

Filters